Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective
Titel:
Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective
Auteur:
Bi, Y. Liu, J. Furmanski, B. Zhao, H. Yu, J. Osgood, C. Ward, A. Keegan, P. Booth, B.P. Rahman, A. Wang, Y.